Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.

Frontiers in pharmacology

Cui H, Wang Q, Miller DD, Li W.
PMID: 33841154
Front Pharmacol. 2021 Mar 25;12:637098. doi: 10.3389/fphar.2021.637098. eCollection 2021.

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15-20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in...

Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.

Drug discovery today

Wang J, Miller DD, Li W.
PMID: 34890803
Drug Discov Today. 2021 Dec 08; doi: 10.1016/j.drudis.2021.12.001. Epub 2021 Dec 08.

Tubulin is an important cancer drug target. Compounds that bind at the colchicine site in tubulin have attracted significant interest as they are generally less affected by multidrug resistance than other potential drugs. Modeling is useful in understanding the...

Editorial Preface for Targeted Cancer Therapy.

Acta pharmaceutica Sinica. B

Chen G, Li W.
PMID: 30109174
Acta Pharm Sin B. 2018 Jul;8(4):501-502. doi: 10.1016/j.apsb.2018.07.003. Epub 2018 Jul 25.

No abstract available.

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-.

Drug designing : open access

Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK.
PMID: 29354330
Drug Des. 2017 Mar;6(1). doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 01.

OBJECTIVE: There is an urgent need drugs against particularly difficult to treat solid tumors such as pancreatic, triple negative breast, lung, colon, metastatic prostate cancers and melanoma. Thus, the objective of this study was to synthesize compounds based computational...

Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.

Drug discovery today

Wang J, Miller DD, Li W.
PMID: 34890803
Drug Discov Today. 2021 Dec 08; doi: 10.1016/j.drudis.2021.12.001. Epub 2021 Dec 08.

Tubulin is an important cancer drug target. Compounds that bind at the colchicine site in tubulin have attracted significant interest as they are generally less affected by multidrug resistance than are other potential drugs. Modeling is useful in understanding...

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies.

Acta pharmaceutica Sinica. B

Bumbaca B, Li W.
PMID: 30109177
Acta Pharm Sin B. 2018 Jul;8(4):518-529. doi: 10.1016/j.apsb.2018.04.007. Epub 2018 Apr 30.

Despite its good initial response and significant survival benefit in patients with castration-resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in all patients. Deep understandings of taxane resistant mechanisms can significantly facilitate the development of new therapeutic...

Recent Advances on Small-Molecule Survivin Inhibitors.

Current medicinal chemistry

Xiao M, Li W.
PMID: 25613234
Curr Med Chem. 2015 Jan 13;22(9):1136 - 1146. doi: 10.2174/0929867322666150114102146.

Survivin, a member of the inhibitor of apoptosisproteins family, is highly expressed in most human neoplasms, but its expression is very low or undetectable in terminally differentiated normal tissues. Survivin has been shown to inhibit cancer cell apoptosis and...

X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.

Journal of medicinal chemistry

Banerjee S, Mahmud F, Deng S, Ma L, Yun MK, Fakayode SO, Arnst KE, Yang L, Chen H, Wu Z, Lukka PB, Parmar K, Meibohm B, White SW, Wang Y, Li W, Miller DD.
PMID: 34406768
J Med Chem. 2021 Sep 09;64(17):13072-13095. doi: 10.1021/acs.jmedchem.1c01202. Epub 2021 Aug 18.

Small molecules that interact with the colchicine binding site in tubulin have demonstrated therapeutic efficacy in treating cancers. We report the design, syntheses, and antitumor efficacies of new analogues of pyridopyrimidine and hydroquinoxalinone compounds with improved drug-like characteristics. Eight...

HIF-1α pathway: role, regulation and intervention for cancer therapy.

Acta pharmaceutica Sinica. B

Masoud GN, Li W.
PMID: 26579469
Acta Pharm Sin B. 2015 Sep;5(5):378-89. doi: 10.1016/j.apsb.2015.05.007. Epub 2015 Jun 06.

Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance...

Showing 1 to 9 of 9 entries